2024-04-10 06:32:00
Designed with the help of artificial intelligence, a vaccine against the recurrence of ENT cancers is giving initial “encouraging results”, reports BFMTV.
There is hope: a vaccine preventing recurrence of certain cancers is in development and is proving promising, even historic. The French biotech Transgene has developed a vaccine intended to prevent relapses of ENT cancers. To achieve this, it relied on artificial intelligence tools, specifies BFMTV. While the first clinical results obtained are described as being “encouraging”new data will be presented in the United States on Wednesday April 10. “Immunotherapy has a limited impact in patients with ENT cancers for whom unfortunately the risks of relapse are high”comments the Institut Curie, in a press release.
Made to measure, the vaccine is thus adapted to the patients’ tumor. To date, around thirty mutations have been identified. These are what make it possible to create a specific treatment. “It is a therapeutic vaccine, which aims to educate the immune system to kill tumor cells that are disseminated throughout the body, to prevent recurrence”explains Olivier Lantz, head of the Clinical Immunology laboratory at the Institut Curie.
Multiple injections
To achieve such a result, the vaccine is injected several times. “Patients are vaccinated every week for six weeks, then every three weeks for a year”, specifies Olivier Lantz to the continuous news channel. The effects are visible “at the end of the six week period” et “this response is maintained over time”, he adds. For the laboratory head, the “historic moment”.
The patients who participate in the tests are all at high risk of relapse, despite initial treatment. But since the injections and a 19-month follow-up, none of them have relapsed. However, drug testing takes time. A second phase of testing should begin in the coming weeks. We will therefore still have to wait a long time before the vaccine is put on the market, which, ultimately, could be adapted to other cancers.
published on April 10 at 8:32 a.m., Cathy Gerig, 6Medias
Share
1712738799
#personalized #vaccine #cancer #recurrence #News